The client’s voice: why they consistently choose Kayentis
At Kayentis, client satisfaction isn’t just a goal—it’s our standard. We pride ourselves on delivering
Key considerations for the implementation of successful Decentralized Clinical Trials (DCTs)
Many chronic diseases such as invasive cancers, inflammatory disorders, cardiovascular, or central nervous system diseases can have a significant impact on patient mobility as well as hindering the ability of caregivers to accompany patients to clinic visits. Hybrid and decentralized clinical trials can provide these patients the opportunity to participate in a clinical trial or even receive a treatment to which they would otherwise not have access.
Decentralized Clinical Trials (DCTs) are recognized as being an integrated and necessary part of the new clinical trial paradigm and require specific considerations in addition to those for site-based clinical trials.
Additionally, the requirements of a particular patient population, protocol design specificities, or regulatory requirements also need to be considered.
Although fully virtual trials are expected to remain quite limited, it is possible that they may become more widespread for certain therapeutic areas such as rare diseases, mental health, central nervous system and neurodegenerative diseases that require patient populations that can’t physically travel or don’t live near a trial site.
As for every innovation, the digitalization of clinical trials comes with its own share of technical challenges.
As patients at home use digital tools in an unsupervised way, it is likely that helpdesk and support services will have to be adapted. Clinical teams will benefit from working with partners who can offer components of DCTs together with close monitoring of patient needs. Additionally, partners will need to be able to provide a platform solution with multiple aspects, including increased support services and adapted back-up strategies, and will need not to rely wholly on technology to ensure that the study conduct flows easily.
The clinical trial industry has been slow to adopt decentralization and until recently, there was little regulation to help the implementation of remote components to clinical trials.
The regulatory landscape evolves continually, but not all regulatory agencies evolve in the same way or at the same pace, which adds complexity for launching DCTs in a wide range of countries. Teams will have to adapt their DCT strategy according to the national laws of the countries where the trial is planned, and promote hybrid strategies that will allow sites in the more traditional countries to still contribute to clinical trials whilst their regulations still need to evolve.
Implementing decentralized components will also mean that the study patients will be in direct contact with an increased number of people and systems. Data privacy concerns will have to be discussed with study teams and safeguards must be in place. This concern can become more significant when Bring Your Own Device (BYOD) is used to support decentralized clinical trials, but relevant security controls can be implemented within the solution.
The FDA recommendation to use remote tools when an in-person site visit is not possible is as a strong driver of regulatory evolution. In situations when a patient is unable to travel to a trial site to provide informed consent, the FDA approves the use of an electronic consent form. Additionally, the use of clinical outcome assessments (COAs) is increasingly recommended to support and enhance patient centricity and diversity in clinical trials.
The EMA recently issued a Guideline on computerised systems and electronic data in clinical trials that should also provide a solid basis for the use of multiple digital technologies in clinical trials.
As the industry becomes increasingly comfortable and knowledgeable about DCTs, this new model will become more mainstream. However, several challenges still remain: protocol specificities will persist whilst technical challenges and clinical staff readiness will evolve. Dealing with data privacy and security rules, for which regulatory bodies remain the ultimate guarantor, will be key. To meet these challenges while keeping patient needs in mind, clinical trial sites and industry stakeholders will need to create a more flexible environment for patient-centric clinical trials.
Learn more:
At Kayentis, client satisfaction isn’t just a goal—it’s our standard. We pride ourselves on delivering
At Kayentis, we value each individual and we form a community that goes beyond the
In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement
In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement
Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating
Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of
Last update : 4 January 2022